Adenocarcinoma of the Gastroesophageal Junction

About
Mappings

OncoTree: Adenocarcinoma of the Gastroesophageal Junction (coding:oncotree:GEJ)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organizations Biomarkers Cancer types Therapies
FDA (1) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Capecitabine
FDA (1) HC (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
FDA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
FDA (1) HC (1) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
FDA (1) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Pembrolizumab
FDA (1) HC (1) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan
FDA (1) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Oxaliplatin, Zolbetuximab
FDA (1) HC (1) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Zolbetuximab
FDA (1) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
FDA (1) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
FDA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab